自引率: 6.8%
被引量: 33320
通过率: 暂无数据
审稿周期: 3.89
版面费用: 暂无数据
国人发稿量: 1562
投稿须知/期刊简介:
Medicine provides insight from leading scholars about the latest results in clinical investigation. Relevant to both hospital and office practice, the journal includes analytical reviews of Internal Medicine, Dermatology, Neurology, Pediatrics, and Reviews in Molecular Medicine. The journal''''''''s timely practice-oriented reports keep you up-to-date about significant clinical observations. Medicine® is now a fully open access journal, providing authors with a distinctive new service offering continuous publication of original research across a broad spectrum of medical scientific disciplines and sub-specialties. As an open access title, Medicine® will continue to provide authors with an established, trusted platform for the publication of their work. To ensure the ongoing quality of Medicine®''''''''s content, the peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines. Medicine® is a fully open access journal, providing authors with a distinctive new service offering continuous publication of original research across a broad spectrum of medical scientific disciplines and sub-specialties. As an open access title, Medicine® will continue to provide authors with an established, trusted platform for the publication of their work. To ensure the ongoing quality of Medicine®'s content, the peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines. The APC for Medicine® is $1650 (USD) for the Creative Commons CCBY -NC license and $1950 for the Creative Commons CCBY license. All Case Reports and Study Protocol articles will be published under the CCBY license. The APC for Case Reports and Study Protocols is $1950.
期刊描述简介:
Medicine provides insight from leading scholars about the latest results in clinical investigation. Relevant to both hospital and office practice, the journal includes analytical reviews of Internal Medicine, Dermatology, Neurology, Pediatrics, and Reviews in Molecular Medicine. The journal''''''''s timely practice-oriented reports keep you up-to-date about significant clinical observations. Medicine® is now a fully open access journal, providing authors with a distinctive new service offering continuous publication of original research across a broad spectrum of medical scientific disciplines and sub-specialties. As an open access title, Medicine® will continue to provide authors with an established, trusted platform for the publication of their work. To ensure the ongoing quality of Medicine®''''''''s content, the peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines.
-
Pembrolizumab alone or combined with chemotherapy versus chemotherapy for the treatment of metastatic cancer: A meta-analysis of randomized clinical trials.
Whether pembrolizumab alone or in combination with chemotherapy is superior to chemotherapy in metastatic cancer remains controversial. The study aims to give the effectiveness and safety of pembrolizumab-related interventions compared to chemotherapy in metastatic cancer. Electronic databases were systematically searched until November 20, 2023, for all randomized controlled trials comparing Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for metastatic cancer. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Hazard ratios (HRs) and odds ratios with 95% confidence intervals (CI) were calculated for OS, PFS, overall response rate, and overall adverse events (AEs) by random effects models. 16 Randomized controlled trials with 9148 patients were included. Compared with chemotherapy, pembrolizumab was associated with longer OS (HR 0.82; 95% CI 0.73-0.91, P = .0004), more immune-mediated AEs, fewer overall AEs, and grade 3 or 4 AEs, however, no significant difference was found in PFS, overall response rate, and events leading to death. Pembrolizumab with chemotherapy was associated with longer OS (HR 0.74; 95% CI 0.61-0.90, P = .002) and PFS (HR 0.63; 95% CI 0.50-0.79, P < .0001), higher overall response rate, and more immune-mediated AEs comparing to chemotherapy alone, however, no significant advantages were observed in disease control rates, overall AEs, grade 3 or 4 AEs and events leading to death. The patients with programmed cell death ligand 1 tumor proportion scores of at least 50% or combined positive scores (CPS) of at least 10 could derive significantly better OS and PFS benefits from pembrolizumab alone or combined with chemotherapy. Similar OS results were found for first-line treatment and lung cancer subgroup analysis. Pembrolizumab alone or combined with chemotherapy indicates an effective and safe treatment for metastatic cancer. Pembrolizumab alone or combined with chemotherapy provides a better survival advantage under first-line treatment or programmed cell death ligand 1 combined positive scores of at least 10 or programmed cell death ligand 1 tumor proportion scores of at least 50%. However, we found that the specific efficacy of pembrolizumab in unused tumor types could not be effectively evaluated.
被引量：- 发表：2024
-
Global research progress of electroencephalography applications in attention deficit hyperactivity disorder: Bibliometrics and visualized analysis.
被引量：- 发表：2024
-
Efficacy of N-acetylcysteine in reducing inflammation and oxidative stress to prevent complex regional pain syndrome type 1.
被引量：- 发表：2024
-
Polymyalgia rheumatica and giant cell arteritis: A bidirectional Mendelian randomization study.
被引量：- 发表：2024
-
Primary osseous leiomyosarcoma of humerus misinterpreted as aneurysmal bone cyst: A case report and literature review.
被引量：- 发表：2024
